Matches in Wikidata for { <http://www.wikidata.org/entity/Q91883193> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q91883193 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91883193 description "scientific article published on 25 July 2019" @default.
- Q91883193 description "wetenschappelijk artikel" @default.
- Q91883193 description "наукова стаття, опублікована 25 липня 2019" @default.
- Q91883193 name "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 name "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 type Item @default.
- Q91883193 label "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 label "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 prefLabel "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 prefLabel "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 P1433 Q91883193-07189710-EEAC-4E91-BC83-B853E766C7DD @default.
- Q91883193 P1476 Q91883193-48AAEE22-5A64-4C9D-BF46-891FF07383C5 @default.
- Q91883193 P2093 Q91883193-2453C1A1-EAAC-4B4C-AF2A-19931DA5C609 @default.
- Q91883193 P2093 Q91883193-2929C55F-F20E-429A-8CDA-5F216D8368F9 @default.
- Q91883193 P2093 Q91883193-5F8E05DD-FA8A-4B43-B445-C91448E9D7F9 @default.
- Q91883193 P2093 Q91883193-8118D132-EEB6-4971-AEC0-1A8C7AF076ED @default.
- Q91883193 P2093 Q91883193-9BD174C8-59F5-45C5-855A-926F36EF6825 @default.
- Q91883193 P2093 Q91883193-A6BF1CA4-2354-4DB1-8AA9-2B61DD3D46CB @default.
- Q91883193 P275 Q91883193-BB3F7D29-7EEB-42BD-8F21-58B7CFAA3416 @default.
- Q91883193 P304 Q91883193-43E1686C-D96B-4F45-857F-C5D4248C54CB @default.
- Q91883193 P31 Q91883193-45878E71-0D37-4B6D-9A8A-8FDFB95D4442 @default.
- Q91883193 P356 Q91883193-853E54DA-8FF7-4DA8-86C2-AE26D9942EB9 @default.
- Q91883193 P50 Q91883193-F3C5A1A8-39F1-4771-8696-0BD700784B7A @default.
- Q91883193 P50 Q91883193-FEC6715B-72B3-4CCD-AD14-DA58861C24F8 @default.
- Q91883193 P577 Q91883193-ADF5BBFD-B8AC-4A45-B702-0D4EC2F9BDF5 @default.
- Q91883193 P6216 Q91883193-F61A0BA8-A0FF-4747-9D8F-44945106BB8D @default.
- Q91883193 P698 Q91883193-D05C3D25-37EE-4270-B941-3C6F1E2C6AD6 @default.
- Q91883193 P921 Q91883193-91A36069-BF2A-4EFE-BAC2-12B3B76D3402 @default.
- Q91883193 P356 00325481.2019.1643633 @default.
- Q91883193 P698 31306043 @default.
- Q91883193 P1433 Q7234297 @default.
- Q91883193 P1476 "Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides" @default.
- Q91883193 P2093 "Craig Granowitz" @default.
- Q91883193 P2093 "Harold E Bays" @default.
- Q91883193 P2093 "Krishnaswami Vijayaraghavan" @default.
- Q91883193 P2093 "Ralph T Doyle" @default.
- Q91883193 P2093 "Rebecca A Juliano" @default.
- Q91883193 P2093 "Sephy Philip" @default.
- Q91883193 P275 Q24082749 @default.
- Q91883193 P304 "1-7" @default.
- Q91883193 P31 Q13442814 @default.
- Q91883193 P356 "10.1080/00325481.2019.1643633" @default.
- Q91883193 P50 Q92433643 @default.
- Q91883193 P50 Q98665268 @default.
- Q91883193 P577 "2019-07-25T00:00:00Z" @default.
- Q91883193 P6216 Q50423863 @default.
- Q91883193 P698 "31306043" @default.
- Q91883193 P921 Q736715 @default.